Healthier Tomorrow

Summary: New preclinical data on AEX-2, a first-in-class dual orexin receptor agonist, highlight its potential to treat narcolepsy, neurodegeneration, and metabolic disorders with a multi-target approach. Key Takeaways: AEX-2 is a novel non-sulfonamide dual orexin receptor agonist that could offer a safer and more targeted alternative to existing orexin-based therapies. In preclinical models, AEX-2 increased…

Summary: A study from the University of Surrey found that morning exposure to blue-enriched light improves sleep quality, increases daytime activity, and promotes regular sleep patterns in older adults living independently, offering a promising, non-pharmacological approach to age-related sleep challenges. Key Takeaways: The study examined the effects of self-administered light exposure, making the intervention more…

Harmony Biosciences provides updates on WAKIX, pitolisant HD, pitolisant GR, and an orexin-2 receptor agonist. In a press release issued this month, Jeffrey M. Dayno, MD, president and CEO of Harmony Biosciences Holdings Inc, says, “2025 is set up to be a transformational year for Harmony, as our robust, late-stage pipeline comes into focus and…

Summary: A new study reveals that even a single night of sleep deprivation can alter immune cell profiles to resemble those seen in obesity, potentially increasing inflammation and the risk of chronic diseases like diabetes and cardiovascular conditions. Key Takeaways:  A single night of sleep deprivation can alter immune cell profiles, making them resemble those…

By Alyx Arnett Sleep specialists can increase their role in the early detection of cardiac comorbidities in sleep apnea patients. Sleep Review’s Cardiology-Sleep Solutions column shares new technologies that can help. Email [email protected] with solutions you’d like to see featured here. Electrocardiogram (ECG) is a standard channel during in-lab polysomnography (PSG) but is generally absent…

Summary: The fifth annual Global Sleep Survey by ResMed reports on the gap between sleep difficulties and taking action to fix them, workplace productivity impacts of lost sleep, sleep’s impact on relationships, and sex differences in sleep.   Key Takeaways: A Global Sleep Survey conducted in December 2024 finds that 7 out of 10 employed respondents…

Summary: Vivos Therapeutics, which markets oral appliances for OSA, has expanded its strategic alliance with Rebis Health after early success with a revenue-sharing model that integrates Vivos-trained dental providers into Rebis sleep centers; with plans to scale nationwide, Vivos aims to improve profitability, expand acquisitions, and position its CARE treatment as a viable CPAP alternative.…

AXS-12 Updates Based on the results of three controlled phase 2 and 3 efficacy trials and a long-term safety trial of AXS-12 in patients with narcolepsy with cataplexy, Axsome Therapeutics Inc expects to submit a new drug application for AXS-12 (reboxetine) for the treatment of cataplexy in patients with narcolepsy to the US Food and…

Summary: Incannex Healthcare reported business highlights for the quarter, including positive top-line results from a pharmacokinetics and safety study of IHL-42X for obstructive sleep apnea, progress in the global phase 2/3 RePOSA trial, the establishment of an OSA clinical advisory board, and a decrease in R&D expenses due to trial completions and resource reallocation. Key…